Edgardo S. Santos Castillero, MD, FACP, discusses current unmet needs in patients with relapsed/refractory non–small cell lung cancer.

Dr Santos Castillero on Unmet Needs to Be Addressed in NSCLC

Edgardo S. Santos Castillero, MD, FACP, medical director, the Oncology Institute of Hope and Innovation; clinical associate professor, thoracic medical oncology, the Charles E. Schmidt College of Medicine, Florida Atlantic University; vice president, the Florida Society of Clinical Oncology (FLASCO); president, the FLASCO Foundation, discusses current unmet needs that remain to be addressed in patients with relapsed/refractory non–small cell lung cancer (NSCLC).

2023 IASLC World Conference on Lung Cancer

, there's a plethora of discussions surrounding lung cancer, Santos Castillero begins. Focusing particularly on early-stage disease, especially in the EGFR-positive space, the phase 3 ADAURA trial (NCT02511106) 

osimertinib (Tagrisso) as the standard of care

 (SOC) for postsurgical patients with NSCLC harboring a sensitizing 

 mutation, such as an EGFR exon 19 deletion or 

 exon 21 mutation, Santos Castillero elucidates. If such mutations are identified, patients are eligible to receive osimertinib, a third-generation EGFR TKI, for a duration of 3 years, he states.

The ADAURA trial, which compared osimertinib with placebo over 3 years, yielded positive results in overall survival (OS), Santos Castillero continues. Patients receiving osimertinib for 3 years had a higher chance of OS at the 5-year mark compared with those who received placebo, he emphasizes. Consequently, osimertinib has become the SOC in the adjuvant setting for patients with stage IB, IIB, and IIIA disease, marking a new indication for its use, Santos Castillero adds.

 (NCT03456076), which followed a comparable design to that of ADAURA, with disease-free survival (DFS) and OS as primary end points, although final OS data are pending, he expands. Based on the ALINA data, oncologists anticipate the potential FDA approval of alectinib (Alecensa), the TKI evaluated in the ALINA trial, for adjuvant use in patients with stage IB to IIIA 

With osimertinib already boasting established OS data in the adjuvant NSCLC setting, the DFS findings with alectinib indicate that this agent will likely receive FDA approval in the same setting, according to Santos Castillero. The key message for this population is the importance of genomic testing for every patient with lung adenocarcinoma undergoing surgery and pathologic staging, Santos Castillero concludes, adding that it's crucial to ascertain whether apatient's tumor harbors 

 alterations, as early-stage therapy should be tailored accordingly.

Videos

Edgardo S. Santos Castillero, MD, FACP, discusses current unmet needs that remain to be addressed in patients with relapsed/refractory non–small cell lung cancer.

NSCLC 2023 Data Updates: Shaping the Future Treatment Landscape

Eduardo Santos, MD, FACP, FCCP, highlights the most impactful and treatment-changing data updates for NSCLC in 2023, and provides perspective on how these finding may shape the future direction of care.

Advances in Dual Immunotherapy Approaches for NSCLC: Data Highlights 2023

Eduardo Santos, MD, FACP, FCCP, discusses recent advances in dual immunotherapy approaches for NSCLC, highlighting data from the CheckMate 9LA study.

Advancements in Squamous NSCLC Treatment: Subgroup Analysis from EMPOWER-Lung Trials

Eduardo Santos, MD, FACP, FCCP, delves into advancements in the treatment of squamous NSCLC, emphasizing crucial insights from the EMPOWER-Lung01 and EMPOWER-Lung03 subgroup analysis.

EMPOWER-Lung3: Evaluating Cemiplimab Plus Chemotherapy in Advanced NSCLC

Eduardo Santos, MD, FACP, FCCP, highlights key takeaways from the latest EMPOWER-LUNG03 data and discusses the impact of these findings on the treatment setting.

Immunotherapy-Based Treatment Strategies in Advanced NSCLC

Eduardo Santos, MD, FACP, FCCP, provides an overview of immunotherapy-based treatment strategies for advanced NSCLC, outlining key factors influencing treatment selection.

Updates in Adjuvant Immunotherapy for NSCLC: Conference Highlights 2023

Dr. Eduardo Santos, MD, FACP, FCCP, examines immunotherapy-based treatment approaches for NSCLC in the adjuvant setting, highlighting updates from KEYNOTE-091.

Advances in Neoadjuvant Immunotherapy for NSCLC: Conference Highlights 2023

Dr. Eduardo Santos, MD, FACP, FCCP, highlights advancements in neoadjuvant immunotherapy for NSCLC presented during key conferences in 2023, underscoring pivotal findings and the potential transformation of treatment approaches.

Immunotherapy-Based Strategies for NSCLC in the Neoadjuvant/Perioperative Setting

Dr. Eduardo Santos, MD, FACP, FCCP, provides and overview of immunotherapy-based treatment strategies for NSCLC in the neoadjuvant and perioperative setting.

Eduardo Santos, MD, FACP, FCCP

Articles